Amgen weight loss data ‘underwhelms,’ says Deutsche Bank
MariTide’s Phase 2 press release “underwhelms” with 20% weight loss from Cohort A and 17% weight loss from Cohort B at 52-weeks, with it being unclear if these are placebo adjusted. MariTide’s weight loss appears to miss the Street’s bogey of 25% weight loss and will weigh down Amgen shares,
Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Mohit ...
Currently, Eli Lilly’s GLP-1 drugs Mounjaro and Zepbound (tirzepatide) are not on the FDA’s shortage list but compounded ...
In today's biotech news, Zepbound trial data, Regenxbio's Duchenne muscular dystrophy treatment, and Intellia's promising ...
Eli Lilly And Co (NYSE:LLY) shares are trading higher Tuesday after the Biden-Harris Administration proposed a new rule to ...
Zepbound, a drug used to help patients lose weight and manage diabetes, may also help those with heart failure, a new trial ...
The Biden administration is proposing a major expansion of how Medicare and Medicaid cover the weight-loss drugs Wegovy and ...
Also Read: 99% Of Mounjaro/Zepbound Patients Remained Diabetes-Free Even At 3 Years, Eli Lilly’s Detailed Phase 3 Data ...
From there, the case for or against investing in Lilly should become much clearer. Eli Lilly's earnings report ...
Should you forget Eli Lilly and buy this magnificent biotech instead? Let's find out. Image source: Getty Images.
The White House said it's moving to make the federal health insurance plans pay for anti-obesity drugs such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound for people who are obese, even if they don ...
The Motley Fool on MSN4d
Billionaire Israel Englander Increased His Stake In Eli Lilly During the Third Quarter: Should You?Eli Lilly lost the momentum it had during the first half of the ... Let's consider just three: First, the company's ...
Investor's Business Daily on MSN1d
Amgen Crashes After Weight-Loss Drug Only Meets Eli Lilly's ZepboundAmgen stock crashed Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback